AccessibilityHelpAbout Us
WuXi Biologics (Cayman) logo

WuXi Biologics (Cayman)(OTC) WXIBF

Market Cap$24.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-13%
5 Year-61%
1 Year+20%
1 Month-3%
$6.01
+0.00%
+0.00Today
WuXi Biologics (Cayman) last closing stock price
MetricPriceDate
Last closeUSD 6.012026-09-21
WuXi Biologics (Cayman) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 6.012026-09-14
1 month-3.06%USD 6.202026-08-21
3 month+50.25%USD 4.002026-06-23
Year to date+42.42%USD 4.222025-12-26
1 year+20.2%USD 5.002025-09-17
3 year+15.36%USD 5.212023-09-20
5 year-60.74%USD 15.312021-09-22
Since inception-12.9%USD 6.902018-01-30

WuXi Biologics (Cayman) Financials at a Glance

Market Cap

$24.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥43.32B

Net Income (TTM)

CN¥9.13B

EPS (TTM)

$0.17

P/E Ratio

34.54

Dividend

$0.00

Beta (Volatility)

0.39 (Low)

Price

$6.01

Volume

21

Open

$6.00

Previous Close

$6.01

Daily Range

$6.00 - $6.01

52-Week Range

$3.90 - $6.45

Estimated Earnings Date

Mar 23, 2027

WXIBF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About WuXi Biologics (Cayman)

WuXi Biologics (Cayman) Inc. is a leading global provider of comprehensive services for the biopharmaceutical industry, covering the entire spectrum from drug discovery to advanced development and manufacturing. The company serves clients across China, North America, Europe, and other international markets, offering expertise in biopharmaceutical technology and contract development.

Products and Services
  • Comprehensive biopharmaceutical services from discovery to manufacturing
  • Contract development and manufacturing organization (CDMO) for vaccines
  • Advanced testing services and clinical support for biologics
Growth Outlook
  • Strong demand for biopharmaceutical services is expected to drive revenue growth
  • Strategic collaborations with key partners enhance market position
  • Expansion into new markets and technologies supports long-term growth
Financial Highlights
  • Recent quarterly revenue of 11.63 billion CNY, reflecting robust performance
  • Net income margin of 20.7% indicates strong profitability
  • Current ratio of 3.04 suggests solid liquidity position
WuXi Biologics has established itself as a vital player in the biopharmaceutical sector, leveraging its extensive service offerings to meet the growing needs of clients worldwide. The company's strategic partnerships and focus on innovation position it well for future growth, particularly as the demand for biopharmaceuticals continues to rise. Recent financial performance highlights a strong revenue base and profitability, underscoring the company's operational efficiency and market strength. With a solid liquidity position, WuXi Biologics is well-equipped to navigate the evolving landscape of the biotechnology industry.
AI Generated • Aug 31, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

13,252

CEO

Zhi Sheng Chen, PhD

Website

www.wuxibiologics.com

Headquarters

Wuxi, JS 214092, CN

WXIBF Financials

Key Financial Metrics (TTM)

Gross Margin

47.47%

Operating Margin

32.36%

Net Income Margin

21.20%

Return on Equity

10.51%

Return on Capital

12.85%

Return on Assets

7.66%

Earnings Yield

2.90%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$24.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.16B

Volume

21

Avg. Volume

3.49K

Financials (TTM)

Gross Profit

CN¥19.60B

Operating Income

CN¥13.41B

EBITDA

CN¥16.47B

Operating Cash Flow

CN¥10.32B

Capital Expenditure

-CN¥5.77B

Free Cash Flow

CN¥4.55B

Cash & ST Invst.

CN¥13.04B

Total Debt

CN¥2.73B

WuXi Biologics (Cayman) Performance Analysis

WuXi Biologics (Cayman) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 2,267,494,59642.1%
20232023-12-31CNY 2,404,260,5846.0%
20242024-12-31CNY 2,594,948,5077.9%
20252025-12-31CNY 3,031,254,84316.8%
WuXi Biologics (Cayman) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3117.8%
Q22025-06-30-1.5%
Q42025-12-3116.9%
Q22026-06-30-0.1%
WuXi Biologics (Cayman) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.1526.3%
20232023-12-31CNY 0.11-27.3%
20242024-12-31CNY 0.11-0.1%
20252025-12-31CNY 0.1648.2%
WuXi Biologics (Cayman) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3122.9%
Q22025-06-3027.9%
Q42025-12-319.1%
Q22026-06-30-5.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥11.63B

+35.6%

Gross Profit

CN¥5.37B

+60.4%

Gross Margin

46.22%

N/A

Market Cap

$24.98BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.88M

N/A

Employees

13,252

N/A

Net Income

CN¥2.41B

+60.5%

EBITDA

CN¥4.33B

+75.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥13.04B

+36.8%

Total Debt

CN¥2.73B

-40.3%

Accounts Receivable

CN¥8.58B

+38.9%

Inventory

CN¥1.82B

-7.1%

Long Term Debt

CN¥2.08B

-40.1%

Short Term Debt

CN¥641.36M

-40.9%

Return on Assets

7.66%

N/A

Return on Invested Capital

13.37%

N/A

Free Cash Flow

CN¥0.00

+100.0%

Operating Cash Flow

CN¥0.00

-100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ORINYOrion Oyj
$46.64-1.60%
ALPMYAstellas Pharma Inc.
$15.21+0.20%
ALPMFAstellas Pharma Inc.
$15.25+10.11%
IVBXFInnovent Biologics, Inc.
$12.53+1.41%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBDWarner Bros. Discovery
$30.80+10.79%
GRMLGreenland Mines
$9.42+230.53%
INTCIntel
$121.78+12.14%
NVDANvidia
$227.38+2.30%

Questions About WXIBF

What is the current price of WuXi Biologics (Cayman)?

WuXi Biologics (Cayman) is trading at $6.01 per share.

What is the 52-week range for WuXi Biologics (Cayman)?

Over the past 52 weeks, WuXi Biologics (Cayman) has traded between $3.90 and $6.45.

How much debt does WuXi Biologics (Cayman) have?

As of the most recent reporting period, WuXi Biologics (Cayman) reported total debt of CN¥444.19M.

How much cash does WuXi Biologics (Cayman) have on hand?

WuXi Biologics (Cayman) reported CN¥1.32B in cash and cash equivalents in its most recent financial results.

What is WuXi Biologics (Cayman)’s dividend yield?

WuXi Biologics (Cayman) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services